Management of inherited thrombophilia in pregnancy

Laura Ormesher, Louise Simcox, Clare Tower, Ian A Greer

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
254 Downloads (Pure)

Abstract

Adverse pregnancy outcomes, such as pregnancy loss and pre-eclampsia, are associated with thrombotic mechanisms and thrombophilia. Antithrombotic interventions, particularly low-molecular-weight heparin, have been investigated in women identified by previous pregnancy outcome; however, the results have been inconsistent. This may reflect heterogeneity of both the study groups and the disease processes resulting in inadequate stratification to guide antithrombotic interventions. Furthermore, the variation in gestation at initiation of low-molecular-weight heparin treatment might be important. Despite limited evidence of efficacy, low-molecular-weight heparin is often used in an attempt to prevent these complications, owing to the lack of other effective treatments and its perceived safety in pregnancy. Research is required to better understand the disease processes, identify possible biomarkers and thereby more homogeneous groups for targeted treatment.
Original languageEnglish
Pages (from-to)433-441
JournalWomen's Health
Volume12
Issue number4
DOIs
Publication statusPublished - 01 Jul 2016

Keywords

  • Anticoagulants
  • Female
  • Humans
  • Placenta Diseases
  • Pregnancy
  • Pregnancy Complications
  • Thrombophilia
  • Journal Article
  • Review

Fingerprint Dive into the research topics of 'Management of inherited thrombophilia in pregnancy'. Together they form a unique fingerprint.

Cite this